Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia
Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL)
Sponsor: German CLL Study Group
Listed as NCT00276848, this PHASE3 trial focuses on Chronic Lymphocytic Leukemia and remains completed. Sponsored by German CLL Study Group, it has been updated 8 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
May 2019 — Jun 2019 [monthly]
Completed PHASE3
-
Jun 2018 — May 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jul 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- German CLL Study Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ansbach, Germany , Arnstadt, Germany , Aschaffenburg, Germany , Augsburg, Germany , Aurich, Germany , Bad Hersfeld, Germany , Bad Mergentheim, Germany , Bad Saarow, Germany , Bad Salzuflen, Germany , Bayreuth, Germany and 89 more locations